Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle, Alejandro Forner, Josep M. Llovet, et al.
Journal of Hepatology (2018) Vol. 69, Iss. 1, pp. 182-236
Closed Access | Times Cited: 10108

Showing 1-25 of 10108 citing articles:

Hepatocellular carcinoma
Josep M. Llovet, Robin Kate Kelley, Augusto Villanueva, et al.
Nature Reviews Disease Primers (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 4472
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry, Bruno Sangro, Thomas Yau, et al.
The Lancet (2017) Vol. 389, Iss. 10088, pp. 2492-2502
Open Access | Times Cited: 3855
Hepatocellular Carcinoma
Augusto Villanueva
New England Journal of Medicine (2019) Vol. 380, Iss. 15, pp. 1450-1462
Closed Access | Times Cited: 3632
A global view of hepatocellular carcinoma: trends, risk, prevention and management
Ju Dong Yang, Pierre Hainaut, Gregory J. Gores, et al.
Nature Reviews Gastroenterology & Hepatology (2019) Vol. 16, Iss. 10, pp. 589-604
Open Access | Times Cited: 3437
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix, Shukui Qin, Philippe Merle, et al.
The Lancet (2016) Vol. 389, Iss. 10064, pp. 56-66
Open Access | Times Cited: 3257
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
María Reig, Alejandro Forner, Jordi Rimola, et al.
Journal of Hepatology (2021) Vol. 76, Iss. 3, pp. 681-693
Open Access | Times Cited: 2794
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Ghassan K. Abou‐Alfa, Tim Meyer, Ann‐Lii Cheng, et al.
New England Journal of Medicine (2018) Vol. 379, Iss. 1, pp. 54-63
Open Access | Times Cited: 2027
Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
Masao Omata, Ann‐Lii Cheng, Norihiro Kokudo, et al.
Hepatology International (2017) Vol. 11, Iss. 4, pp. 317-370
Open Access | Times Cited: 1890
Molecular therapies and precision medicine for hepatocellular carcinoma
Josep M. Llovet, Robert Montal, Daniela Sia, et al.
Nature Reviews Clinical Oncology (2018) Vol. 15, Iss. 10, pp. 599-616
Open Access | Times Cited: 1632
Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
Jordi Bruix, María Reig, Morris Sherman
Gastroenterology (2016) Vol. 150, Iss. 4, pp. 835-853
Open Access | Times Cited: 1571
Epidemiology and Management of Hepatocellular Carcinoma
Laura Kulik, Hashem B. El–Serag
Gastroenterology (2018) Vol. 156, Iss. 2, pp. 477-491.e1
Open Access | Times Cited: 1502
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu, Yoon‐Koo Kang, Chia‐Jui Yen, et al.
The Lancet Oncology (2019) Vol. 20, Iss. 2, pp. 282-296
Closed Access | Times Cited: 1436
Hepatocellular carcinoma
Arndt Vogel, Tim Meyer, Gonzalo Sapisochín, et al.
The Lancet (2022) Vol. 400, Iss. 10360, pp. 1345-1362
Closed Access | Times Cited: 1345
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Daniel Q. Huang, Hashem B. El–Serag, Rohit Loomba
Nature Reviews Gastroenterology & Hepatology (2020) Vol. 18, Iss. 4, pp. 223-238
Open Access | Times Cited: 1344
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
John Bridgewater, Peter R. Galle, Shahid A. Khan, et al.
Journal of Hepatology (2014) Vol. 60, Iss. 6, pp. 1268-1289
Open Access | Times Cited: 1333
Hepatocellular carcinoma: clinical frontiers and perspectives
Jordi Bruix, Gregory J. Gores, Vincenzo Mazzaferro
Gut (2014) Vol. 63, Iss. 5, pp. 844-855
Open Access | Times Cited: 1279
Immunotherapies for hepatocellular carcinoma
Josep M. Llovet, Florian Castet, Mathias Heikenwälder, et al.
Nature Reviews Clinical Oncology (2021) Vol. 19, Iss. 3, pp. 151-172
Closed Access | Times Cited: 1170
Genetic Landscape and Biomarkers of Hepatocellular Carcinoma
Jessica Zucman‐Rossi, Augusto Villanueva, Jean‐Charles Nault, et al.
Gastroenterology (2015) Vol. 149, Iss. 5, pp. 1226-1239.e4
Open Access | Times Cited: 1163
EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis
Gideon M. Hirschfield, Ulrich Beuers, Christophe Corpechot, et al.
Journal of Hepatology (2017) Vol. 67, Iss. 1, pp. 145-172
Open Access | Times Cited: 1149
From NASH to HCC: current concepts and future challenges
Quentin M. Anstee, Helen L. Reeves, Elena Kotsiliti, et al.
Nature Reviews Gastroenterology & Hepatology (2019) Vol. 16, Iss. 7, pp. 411-428
Closed Access | Times Cited: 1147
Global burden of primary liver cancer in 2020 and predictions to 2040
Harriet Rumgay, Melina Arnold, Jacques Ferlay, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 6, pp. 1598-1606
Open Access | Times Cited: 1120
Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study
Joong‐Won Park, Minshan Chen, M. Colombo, et al.
Liver International (2015) Vol. 35, Iss. 9, pp. 2155-2166
Open Access | Times Cited: 1013
Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis
Daniela Sia, Augusto Villanueva, Scott L. Friedman, et al.
Gastroenterology (2016) Vol. 152, Iss. 4, pp. 745-761
Open Access | Times Cited: 1009
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
Jordi Bruix, Tadatoshi Takayama, Vincenzo Mazzaferro, et al.
The Lancet Oncology (2015) Vol. 16, Iss. 13, pp. 1344-1354
Closed Access | Times Cited: 978
New trends on obesity and NAFLD in Asia
Jian-Gao Fan, Seung Up Kim, Vincent Wai‐Sun Wong
Journal of Hepatology (2017) Vol. 67, Iss. 4, pp. 862-873
Open Access | Times Cited: 977
Page 1 - Next Page

Scroll to top